or her records or otherwise provide enough information to enable the identification of the individual's record; (3) identify the information that the individual believes is not accurate, relevant, timely or complete; (4) indicate what corrective action is sought; and (5) include supporting justification or documentation for the requested amendment. Verification of identity as described in the Department's Privacy Act regulations may be required. 45 CFR 5b.5.

RECORD SOURCE CATEGORIES:
Information is obtained from individuals and organizations, including third parties conducting business on behalf of a business or organization, that apply for access privileges to the FPLS Child Support Services Portal and its services.

EXEMPTIONS CLAIMED FOR THE SYSTEM:
None.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Safety and Occupational Health Study Section: Notice of Charter Renewal

This gives notice under the Federal Advisory Committee Act (Pub. L. 92–463) of October 6, 1972, that the Safety and Occupational Health Study Section, Centers for Disease Control and Prevention, Department of Health and Human Services, has been renewed for a 2-year period through June 30, 2012.

FOR FURTHER INFORMATION CONTACT:
Price Connor, PhD, Executive Secretary, Safety and Occupational Health Study Section, Department of Health and Human Services, 1600 Clifton Road, NE., Mailstop E74, Atlanta, Georgia 30333, telephone 404/498–2511 or fax 404/498–2571.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: July 13, 2010.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Food and Drug Administration [Docket No. FDA–2010–N–0318]

Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 27 New Drug Applications and 58 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 27 new drug applications (NDAs) and 58 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

DATES: Effective Date: August 20, 2010.

FOR FURTHER INFORMATION CONTACT:

SUPPLEMENTARY INFORMATION: The holders of the applications listed in table 1 of this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications pursuant to the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.

<table>
<thead>
<tr>
<th>Application No.</th>
<th>Drug Description</th>
<th>Applicant</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA 6–008</td>
<td>Mesantoin (mephenytoin) Tablets</td>
<td>Novartis Pharmaceuticals Corp., One Health Plaza, East Hanover, NJ 07936–1080</td>
</tr>
<tr>
<td>NDA 9–000</td>
<td>Cefergot (ergotamine tartrate and caffeine) Suppository, 1 milligram (mg)/100 mg and 2 mg/100 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>NDA 9–561</td>
<td>Hypaque (diatrizoate sodium)</td>
<td>GE Healthcare, Inc., 101 Carnegie Center, Princeton, NJ 08540</td>
</tr>
<tr>
<td>NDA 9–658</td>
<td>Hydrocortisone Tablets</td>
<td>Smith, Miller and Patch, Inc., Division of Cooper Vision, Inc., c/o Cooper Laboratories, Inc., 455 E. Middlefield Rd., Mountain View, CA 94043</td>
</tr>
<tr>
<td>NDA 9–942</td>
<td>Deltra (prednisone) Tablets</td>
<td>Merck &amp; Co., Inc., P.O. Box 4, BLA–20, West Point, PA 19486–0004</td>
</tr>
<tr>
<td>NDA 10–051</td>
<td>Hydeltra (prednisolone) Tablets</td>
<td>Do.</td>
</tr>
<tr>
<td>NDA 10–255</td>
<td>Meticortelone (prednisolone acetate) Injection and Suspension</td>
<td>Schering Corp., Galloping Hill Rd., Kenilworth, NJ 07033</td>
</tr>
<tr>
<td>NDA 12–885</td>
<td>Winstrol (stanozolol) Tablets, 2 mg</td>
<td>Lundbeck, Inc., Four Parkway North, Deerfield, IL 60015</td>
</tr>
<tr>
<td>NDA 13–428</td>
<td>Valpin (anisotropine methylbromide) Tablets</td>
<td>Endo Pharmaceuticals, 100 Endo Blvd., Chadds Ford, PA 19317</td>
</tr>
</tbody>
</table>